Loading...
•
Mar 31, 2021
Viking Therapeutics Q1 2021 Earnings Report
Viking Therapeutics reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Viking Therapeutics reported a net loss of $14.0 million, or $0.19 per share, for the first quarter ended March 31, 2021. The company's cash, cash equivalents, and short-term investments totaled $241.7 million at the end of the quarter.
U.S. and European sites continue to enroll Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH.
Phase 1 study evaluating VK0214 in healthy volunteers is ongoing; the company expects to initiate a proof-of-concept trial in X-ALD patients mid-2021.
Viking completed the first quarter of 2021 with $241.7 million in cash, cash equivalents and short-term investments.
The company remains on track to complete enrollment in the VOYAGE trial in the second half of 2021.
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking Therapeutics is focused on the development of novel therapies for metabolic and endocrine disorders.
Positive Outlook
- Enrollment continues in Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH.
- VK2809 has demonstrated promising therapeutic potential in a range of lipid disorders.
- Phase 1 study evaluating VK0214 in healthy volunteers is ongoing.
- VK0214 is being evaluated as a potential treatment for X-linked adrenoleukodystrophy (X-ALD).
- Strong balance sheet provides runway to complete multiple key clinical milestones.
Challenges Ahead
- Risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials
- Risks that prior clinical and preclinical results may not be replicated
- Risks regarding regulatory requirements
- Risks related to the COVID-19 pandemic
- Viking disclaims any obligation to update these forward-looking statements except as required by law.